Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

23 septembre 2026 mis à jour par: HighField Biopharmaceuticals Corporation

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of HF50 in Patients With Advanced Solid Tumors

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.

Type d'étude

Interventionnel

Inscription (Estimé)

45

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100021
        • Pas encore de recrutement
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Contact:
          • FEI MA, MD,PhD
        • Chercheur principal:
          • FEI MA, MD,PhD
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510120
        • Recrutement
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Chercheur principal:
          • Jing Li, MD, PhD
        • Chercheur principal:
          • Qiong Yang, MD, PhD
        • Contact:
        • Chercheur principal:
          • HERUI YAO, MD,PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Voluntary participation: Capable of giving signed informed consent and able to comply with all study-related procedures.
  • Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
  • Disease Status: Participants with histologically or cytologically confirmed advanced solid tumors that are unresectable or metastatic, who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include HER2-expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
  • Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  • Life Expectancy: Anticipated survival of no less than 6 months.
  • Measurable Disease: At least one measurable lesion according to RECIST v1.1 definitions.
  • Organ and Bone Marrow Function:

Bone Marrow Reserve: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, lymphocyte count >= 1.0 x 10^9/L, platelet count >= 90 x 10^9/L, and hemoglobin >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).

Coagulation Function: Activated partial thromboplastin time (APTT) <= 1.5 x ULN, and International Normalized Ratio (INR) <= 1.5.

Liver Function: Total bilirubin (TBIL) <= 1.5 x ULN, and ALT and AST <= 2.5 x ULN. For participants with liver metastases: ALT and AST <= 5 x ULN, and TBIL <= 3 x ULN.

Renal Function: Creatinine clearance >= 50 mL/min (calculated using the Cockcroft-Gault formula).

  • Contraception: Participants of reproductive potential (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of childbearing potential must have a negative serum pregnancy test during screening and prior to the first dose.

Exclusion Criteria:

  • Autoimmune Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema < 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
  • Corticosteroids/Immunosuppressants: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
  • Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
  • CNS Metastasis: Clinically symptomatic brain or meningeal metastases. Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
  • Toxicity Recovery: Failure to recover from all adverse events of prior therapies to <= Grade 1 (NCI CTCAE v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
  • Cardiovascular History: Including thromboembolic events within 3 months; NYHA Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
  • Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
  • Viral Infection: HIV infection, active HBV (HBV DNA > ULN), or active HCV (HCV RNA > ULN).
  • Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
  • Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
  • Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: HF50

HF50 monotherapy

HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants with Dose Limiting Toxicities (DLT)
Délai: 28 days after the first dose (C1D1) for each dose cohort.

The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD).

28 days after the first dose (C1D1) for each dose cohort.
Incidence of Adverse Events (AEs)
Délai: From first dose to 28 days after the last dose.

The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0

From first dose to 28 days after the last dose.
Recommended Phase II Dose (RP2D) of HF50
Délai: At the end of dose escalation (assessed up to 1 year)

RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase.

At the end of dose escalation (assessed up to 1 year)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Objective Response Rate (ORR)
Délai: Up to 2 years

Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria.

Up to 2 years
Duration of Response (DOR)
Délai: Up to 2 years

Time from the first documented response (CR or PR) to disease progression or death.

Up to 2 years
Disease Control Rate (DCR)
Délai: Up to 2 years

Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1.

Up to 2 years
Progression-Free Survival (PFS)
Délai: Up to 2 years

Time from the first dose to disease progression or death.

Up to 2 years
Overall Survival (OS)
Délai: Up to 2 years

Time from the first dose to death from any cause.

Up to 2 years
Pharmacokinetic Parameter - Cmax
Délai: Up to 2 years

Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - Tmax
Délai: Up to 2 years

Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing.

Up to 2 years
Pharmacokinetic Parameter - AUC (Area Under the Curve)
Délai: Up to 2 years

AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50.

Up to 2 years
Pharmacokinetic Parameter - Half-life (t1/2)
Délai: Up to 2 years

The terminal elimination half-life (t1/2) of HF50 will be calculated.

Up to 2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: HERUI YAO, MD,PhD, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 septembre 2026

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

15 mai 2026

Première soumission répondant aux critères de contrôle qualité

15 mai 2026

Première publication (Réel)

22 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • HF50-102

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .